Search - tctmd.com

Displaying 501 - 520 of 592

Sort: Relevancy | Date

News Daily News

El USPSTF Refuerza las Recomendaciones en materia de Prevención Primaria al asegurar que la Aspirina Solo Debería de Emplearse en Sujetos de Riesgo Alto

Michael O'Riordan

April 12, 2016

News Conference News ACC 2016

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

Michael O'Riordan

April 03, 2016

News Conference News ACC 2016

HOPE-3: Reducing LDL Cholesterol Improves Outcomes in Intermediate-Risk Patients, but BP-Lowering Does Not

Michael O'Riordan

April 02, 2016

News Daily News

ACC 更新降低低密度脂蛋白胆固醇降低的建议，为依折麦布和 PCSK9 抑制剂留出了空间

Michael O'Riordan

April 02, 2016

News Daily News

ACC Updates LDL-Cholesterol Lowering Recommendations, Making Room for Ezetimibe and PCSK9 Inhibitors

Michael O'Riordan

April 02, 2016

News Daily News

ACC actualiza las recomendaciones para bajar el colesterol LBD, abriendo un espacio para el uso de Ezetimibe y de los inhibidores de PCSK9

Michael O'Riordan

April 02, 2016

News Daily News

双倍剂量的氯吡格雷可以解决“吸烟者悖论”：GRAVITAS 分析

Michael O'Riordan

February 28, 2016

News Daily News

Análisis del Ensayo GRAVITAS: La ‘Paradoja del Fumador’ Desaparece con Dosis Dobles de Clopidogrel

Michael O'Riordan

February 28, 2016

News Daily News

‘Smoker’s Paradox’ Eliminated With Double Dose of Clopidogrel: GRAVITAS Analysis

Michael O'Riordan

February 28, 2016

News Industry News

Meta-Analysis of AGGRASTAT® (Tirofiban HCl) Presented at CRT 2016 Conference

February 22, 2016

News Daily News

研究认为有数据支持针对患者风险而非 LDL 胆固醇目标进行治疗

Michael O'Riordan

February 15, 2016

News Daily News

Según un Informe los Datos Avalan Tratar el Riesgo de los Pacientes No las Dianas de Colesterol LBD

Michael O'Riordan

February 15, 2016

News Daily News

Data Support Treating Patient Risk, Not LDL Cholesterol Targets, Paper Argues

Michael O'Riordan

February 15, 2016

News Daily News

Statins Possibly Protect Against Death, CV Events in Asymptomatic PAD PatientsLas Estatinas Podrían Proteger frente a la Muerte y los Episodios CV en Pacientes EAP Asintomáticos

Caitlin E. Cox

February 08, 2016

News Daily News

他汀类药物可能会保护无症状 PAD 患者免于死亡、心血管事件

Caitlin E. Cox

February 08, 2016

News Daily News

Statins Possibly Protect Against Death, CV Events in Asymptomatic PAD Patients

Caitlin E. Cox

February 08, 2016

News Daily News

在他汀类药物治疗基础上添加依泽替米贝可以降低首次和后续心血管事件的风险：IMPROVE-IT 分析

Michael O'Riordan

January 26, 2016

News Daily News

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

Michael O'Riordan

January 26, 2016

News Daily News

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Michael O'Riordan

January 26, 2016

News Features

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Michael O'Riordan

January 25, 2016

Advertisement

El USPSTF Refuerza las Recomendaciones en materia de Prevención Primaria al asegurar que la Aspirina Solo Debería de Emplearse en Sujetos de Riesgo Alto

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

HOPE-3: Reducing LDL Cholesterol Improves Outcomes in Intermediate-Risk Patients, but BP-Lowering Does Not

ACC 更新降低低密度脂蛋白胆固醇降低的建议，为依折麦布和 PCSK9 抑制剂留出了空间

ACC Updates LDL-Cholesterol Lowering Recommendations, Making Room for Ezetimibe and PCSK9 Inhibitors

ACC actualiza las recomendaciones para bajar el colesterol LBD, abriendo un espacio para el uso de Ezetimibe y de los inhibidores de PCSK9

双倍剂量的氯吡格雷可以解决“吸烟者悖论”：GRAVITAS 分析

Análisis del Ensayo GRAVITAS: La ‘Paradoja del Fumador’ Desaparece con Dosis Dobles de Clopidogrel

‘Smoker’s Paradox’ Eliminated With Double Dose of Clopidogrel: GRAVITAS Analysis

Meta-Analysis of AGGRASTAT® (Tirofiban HCl) Presented at CRT 2016 Conference

研究认为有数据支持针对患者风险而非 LDL 胆固醇目标进行治疗

Según un Informe los Datos Avalan Tratar el Riesgo de los Pacientes No las Dianas de Colesterol LBD

Data Support Treating Patient Risk, Not LDL Cholesterol Targets, Paper Argues

Statins Possibly Protect Against Death, CV Events in Asymptomatic PAD PatientsLas Estatinas Podrían Proteger frente a la Muerte y los Episodios CV en Pacientes EAP Asintomáticos

他汀类药物可能会保护无症状 PAD 患者免于死亡、心血管事件

Statins Possibly Protect Against Death, CV Events in Asymptomatic PAD Patients

在他汀类药物治疗基础上添加依泽替米贝可以降低首次和后续心血管事件的风险：IMPROVE-IT 分析

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content